Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jianhua Ling

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1315-4389; OpenAlex author ID A5044222908. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
75
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 1 paper · 2020: 1 paper · 2021: none · 2022: 3 papers · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 17

  1. All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Co-author DOI 10.1038/s41467-026-72271-5↗
  2. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. First author DOI 10.1038/s41467-024-47242-3↗
  3. All-trans retinoic acid-mediated ADAR1 degradation synergizes with PD-1 blockade to suppress pancreatic cancer Co-author DOI 10.1101/2024.10.20.619300↗
  4. Smad4 Deficiency Promotes Pancreatic Cancer Immunogenicity by Activating the Cancer-Autonomous DNA-Sensing Signaling Axis. Co-author DOI 10.1002/advs.202103029↗
  5. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1172/jci151604↗
  6. Recombinant Thrombomodulin Has Anti-tumor Effects and Enhances the Effects of Gemcitabine for Pancreatic Cancer Through G-protein Coupled Receptor 15. First author DOI 10.21873/anticanres.15972↗
  7. The overexpression of long intergenic ncRNA00162 induced by RelA/p65 promotes growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cpr.12805↗
  8. Two Birds with One Stone: Therapeutic Targeting of IL1α Signaling Pathways in Pancreatic Ductal Adenocarcinoma and the Cancer-Associated Fibroblasts. Co-author DOI 10.1158/2159-8290.cd-18-1460↗
  9. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer. Co-author DOI 10.1038/onc.2017.393↗
  10. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1126/scitranslmed.aat3487↗
  11. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation. Co-author DOI 10.1016/j.canlet.2017.09.018↗
  12. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/ncomms14437↗
  13. Inhibition of Pancreatic Cancer by RhIL1RA-Response. First author DOI 10.1158/1078-0432.ccr-17-0083↗
  14. IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation. Co-author DOI 10.1158/1078-0432.ccr-14-3382↗
  15. Transforming Growth Factor-β Limits Secretion of Lumican by Activated Stellate Cells within Primary Pancreatic Adenocarcinoma Tumors. Co-author DOI 10.1158/1078-0432.ccr-15-2780↗
  16. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccr.2011.12.006↗
  17. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. Co-author DOI 10.1093/jnci/djr243↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paul J. Chiao · 16 shared papers, 2011–2026 · strength 1.61
  2. Jie Fu · 8 shared papers, 2016–2026 · strength 0.96
  3. Anirban Maitra · 5 shared papers, 2018–2026 · strength 0.69
  4. Huamin Wang · 7 shared papers, 2012–2026 · strength 0.65
  5. Mien‐Chie Hung · 6 shared papers, 2012–2026 · strength 0.65
  6. Ching-Fei Li · 3 shared papers, 2024–2026 · strength 0.51
  7. Lu Yu · 5 shared papers, 2017–2024 · strength 0.47
  8. Kenei Furukawa · 3 shared papers, 2020–2024 · strength 0.44
  9. Haoqiang Ying · 3 shared papers, 2017–2026 · strength 0.42
  10. Jason B. Fleming · 5 shared papers, 2012–2024 · strength 0.37
  11. Yongkun Wei · 2 shared papers, 2024–2026 · strength 0.37
  12. Ying‐Nai Wang · 2 shared papers, 2024–2026 · strength 0.37
  13. Li‐Yuan Bai · 2 shared papers, 2024–2026 · strength 0.37
  14. Dihua Yu · 2 shared papers, 2024–2026 · strength 0.37
  15. Ya’an Kang · 4 shared papers, 2012–2024 · strength 0.33
  16. Peng Huang · 3 shared papers, 2017–2024 · strength 0.31
  17. Cheng‐Wei Chou · 1 shared paper, 2026 · strength 0.21
  18. Wantong Yao · 1 shared paper, 2026 · strength 0.21
  19. Jun Yao · 2 shared papers, 2017–2024 · strength 0.20
  20. Jeffrey E. Lee · 2 shared papers, 2018–2022 · strength 0.18
  21. Jie Fu · 2 shared papers, 2017–2018 · strength 0.17
  22. Ronald Anthony Depinho · 2 shared papers, 2017–2022 · strength 0.17
  23. Zhuonan Zhuang · 3 shared papers, 2016–2017 · strength 0.16
  24. Huai‐Qiang Ju · 3 shared papers, 2016–2017 · strength 0.16
  25. Matthew H. G. Katz · 2 shared papers, 2016–2022 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.